Pancragen peptide benefits reported in the published literature are set out below with the endpoints each study actually measured. Pancragen is a lyophilized vial of the tetrapeptide Lys-Glu-Asp-Trp, written KEDW, the pancreas-directed compound in the Khavinson range.
Specification Table
Pancragen verified chemical and handling data
| Property |
Value |
| Compound |
Pancragen |
| Sequence designation |
KEDW |
| Amino acid sequence |
Lysine-Glutamate-Aspartate-Tryptophan |
| Residue count |
4 |
| Approximate molecular weight |
561.6 g/mol for the free tetrapeptide |
| Oxidation-prone residues |
Tryptophan at position 4 |
| Chromophore |
Tryptophan, giving 280 nm absorbance |
| Compound class |
Short peptide bioregulator, cytogen subclass |
| Cytogen versus cytomax |
Cytogen. A laboratory-synthesised defined sequence, not a tissue extract |
| Source tissue of the parent fraction |
Pancreatic tissue |
| Originating programme |
St Petersburg Institute of Bioregulation and Gerontology |
| Programme lead |
Vladimir Khavinson |
| Proposed mechanism in the literature |
Sequence-specific interaction with DNA, modulating tissue-associated gene expression |
| Mechanism status |
Hypothesis. Not independently established outside the originating programme |
| Receptor |
None identified |
| Appearance |
White lyophilized powder |
| Purity |
Per lot-specific certificate of analysis |
| Solubility |
Water soluble |
| Storage, lyophilized |
2-8°C or -20°C, protected from light and moisture |
| Regulatory status |
No approved human or veterinary formulation in any jurisdiction |
What Do Pancragen Peptide Benefits Studies Measure?
The Pancragen peptide benefits phrasing is broader than what the published endpoints actually cover, and stating the gap is more useful than filling it with implication.
Published work from the originating programme reports measurements in pancreatic tissue in aged rodent models, including histological assessment of islet architecture and markers of tissue-associated gene expression.
Cell-culture work in the family reports changes in proliferation and differentiation markers in pancreatic-derived lines, though the primary literature on this specific sequence is thinner than on Epitalon or Vilon.
What the record does not contain is a well-powered independent Western clinical trial. That absence is the defining feature of the entire bioregulator literature and it applies here as it does across the family.
The measured endpoints are therefore tissue-level and gene-expression observations in models, reported by one research programme over several decades. That is a real body of work and it supports a narrower claim than the search term implies.
Why Does the Tryptophan Change the Handling?
Pancragen peptide is the only member of this family carrying tryptophan, and that single residue makes it the least stable compound in the range.
Tryptophan oxidises readily, adding 16 daltons and producing a family of oxidation products, and it is photosensitive as well, degrading under ultraviolet and more slowly under ambient light.
Every other bioregulator covered in this catalogue lacks tryptophan, methionine and cysteine entirely, which is why they tolerate handling that would degrade an ordinary peptide. Pancragen does not share that immunity.
The practical consequences are specific. Protect from light throughout, including during weighing and reconstitution. Minimise headspace air exposure and avoid leaving the vial open on a bench.
On the useful side, the same tryptophan provides strong absorbance at 280 nanometres, so concentration determination requires no standard curve once the extinction coefficient is known. Every other compound in this family needs amino acid analysis or a colorimetric assay instead.
A plus-16 satellite on the mass spectrum is the direct oxidation check, and with a single oxidisable residue the interpretation is unambiguous.
What Is a Pancreas Bioregulator?
The organ term appears in search far more often than Pancragen peptide does, and it describes the organising idea behind the whole Khavinson programme.
The programme fractionated animal tissue extracts over several decades, working from the premise that extracts from a given organ contain short peptides carrying regulatory information specific to that tissue.
Each compound in the family is named for its source organ rather than for its sequence. Pancragen came from pancreatic tissue, Livagen from liver, Cardiogen from heart, Bronchogen from bronchial tissue, and so on.
The class divides in two. Cytomaxes are peptide-containing tissue extracts, while cytogens are laboratory-synthesised short sequences designed to reproduce the extract activity. Pancragen is a cytogen, meaning a defined tetrapeptide rather than a fraction.
That distinction matters analytically. A synthetic tetrapeptide can be characterised completely by mass spectrometry and chromatography. A tissue extract cannot, and claims made about one do not transfer to the other.
Searching by organ rather than trade name is what most people actually do, which is why this page claims the organ term deliberately rather than leaving it to chance.
What Pancragen Peptide Dosage Figures Are Published?
The figures below come from published studies in the species those studies used, and the caveats attached to the family apply.
Rodent work has used amounts broadly in the microgram per kilogram range by parenteral routes. That is consistent with the rest of the Khavinson family, and low.
The Russian clinical record describes courses running ten to twenty days at amounts in the tens to low hundreds of micrograms, structured as discrete courses rather than as continuous exposure over an open-ended period.
That course structure is a consistent feature of how these compounds are described and it differs from the continuous-exposure designs common elsewhere in peptide research. Anyone reproducing published work should match the structure as well as the amount.
No receptor affinity is known, so there is no pharmacological basis for narrowing a concentration range. Wide concentration ranging is a requirement rather than good practice.
Allometric scaling through body surface area is required for any cross-species comparison, and the FDA conversion factors are the standard method.
What Should Buying Pancragen Bioregulator Involve Checking?
Pancragen peptide at four residues is straightforward to characterise, and the tryptophan adds one check the rest of the family does not need.
Mass against roughly 561.6 for the free tetrapeptide. Ask for the oxidised fraction quantified rather than merely absent from the report, because absence on a certificate usually means it was never measured.
Purity by reversed-phase chromatography, noting that the tryptophan gives this peptide considerably more retention than its shorter relatives, so a method developed here may not transfer to Vilon or Chonluten at all.
Counterion identity with net peptide content. At 561.6 daltons a trifluoroacetate at 114 is roughly 17 percent of the associated mass, which is a large correction though smaller than Vilon.
Sequence stated as Lys-Glu-Asp-Trp explicitly. Several compounds in this family differ by a single residue, and trade names carry no information about what is inside the vial.
Storage conditions during transit, since a tryptophan-containing peptide shipped warm and light-exposed arrives in a different condition from one shipped properly.
How Should Pancragen Peptide Benefits Claims Be Read?
Search demand for this phrasing is real and the honest answer separates three things that get merged.
The chemistry is settled. Lys-Glu-Asp-Trp is a defined tetrapeptide of known mass and composition, synthesisable to high purity and fully characterisable by routine analysis.
The research record is documented. The St Petersburg programme published across several decades, and the tissue-level and gene-expression observations reported for this compound are real measurements in real models.
The mechanism is not established. The DNA-binding proposal has support from within the originating programme and limited independent structural confirmation, and it conflicts with the conventional understanding of how sequence-specific DNA recognition works.
Merging those three is what produces overclaiming. A compound can have settled chemistry, a documented research history and an unresolved mechanism at the same time, and every Khavinson bioregulator does.
Reading published Pancragen peptide benefits claims against that three-way split is the fastest way to tell a defensible statement from an inherited one.
How Should the Vial Be Stored and Divided?
With Pancragen peptide, protect from light first and everything else second.
Hold lyophilized material at 2 to 8 degrees Celsius or colder, sealed against light and moisture, in an opaque container or its original packaging.
Reconstituted solution at 2 to 8 degrees in the dark, aliquoted before freezing, because unlike its tryptophan-free relatives this compound does not tolerate casual handling indefinitely.
Water solubility is good, so add diluent slowly down the vial wall and swirl rather than shaking.
Check concentration spectrophotometrically at 280 nanometres before critical work rather than relying on the nominal figure. That option is available here and nowhere else in this family.
Record lot, counterion, net peptide content, diluent, volume, measured concentration, and the date, plus any light exposure during handling.
A closing note on sourcing across this family. Because several bioregulators differ by a single residue, a supplier shipping the wrong vial produces a product that looks identical and analyses differently only on close inspection.
Livagen is Lys-Glu-Asp-Ala and Pancragen is Lys-Glu-Asp-Trp. The two differ by one residue and roughly 115 daltons, which is obvious on a mass spectrum and invisible on a label.
Asking for the measured mass rather than accepting the trade name is therefore worth more in this family than almost anywhere else in the catalogue.
The tryptophan makes Pancragen the easiest of the group to confirm, since it is the only one with a 280 nanometre signal to check against.
One further note on the family and analysis. Because most of these compounds lack any chromophore, laboratories working across several of them end up needing amino acid analysis as a routine rather than an exception.
Budgeting for that up front is more sensible than discovering it partway through a comparison study, and it is the single most common practical surprise in this compound family.
A last note on the organ naming. Because each compound is named for its source tissue rather than its sequence, the trade names carry an implied claim about where the compound acts.
That implication is inherited from the fractionation methodology rather than demonstrated by tissue-distribution work, and it is worth holding at arm length when reading the family literature.
Tissue-distribution studies would settle it directly, and their absence across the whole family is one of the clearer gaps in this literature.
Until they exist, the organ names should be read as programme labels describing where a compound came from rather than established statements about where it goes.
That gap is not small.
A programme that named sixteen compounds after sixteen organs, across five decades of publication, without ever publishing a systematic tissue-distribution comparison across them, has left the single most testable version of its own central claim unexamined, and that is worth stating plainly rather than working around.
Someone will run it eventually.
Published Literature
References verified against the publisher record. As with every compound in this family, the literature originates almost entirely from one research programme.
- Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel; 2005.
- Khavinson VK. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144.
- Anisimov VN, Khavinson VK. Critical Reviews in Oncology/Hematology. 2010;74(1):46-66.
- Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Biochemistry (Moscow). 2011;76(11):1210-1219.
- Khavinson VK, Solovyov AY, Zhilinsky DV, Shataeva LK, Bandaletova TY. Bulletin of Experimental Biology and Medicine. 2012;153(4):500-505.
Frequently Asked Questions
What is Pancragen peptide?
A lyophilized vial of the tetrapeptide Lys-Glu-Asp-Trp, written KEDW, the pancreas-directed compound in the Khavinson bioregulator range. Laboratory research use only, with no approved formulation anywhere.
What do the research endpoints cover?
Measurements in pancreatic tissue in aged rodent models, including histological assessment of islet architecture and markers of tissue-associated gene expression, plus cell-culture work on proliferation and differentiation markers.
What is missing from the record?
A well-powered independent Western clinical trial. That absence defines the entire bioregulator literature and applies to this compound as it does across the family.
Why does the tryptophan matter?
Because it makes Pancragen the least stable compound in this family. Tryptophan oxidises readily, adding 16 daltons, and it is photosensitive. Every other bioregulator here lacks tryptophan, methionine and cysteine entirely.
Is there an upside to it?
Yes. Tryptophan gives strong absorbance at 280 nanometres, so concentration can be determined spectrophotometrically without a standard curve. Every other compound in this family needs amino acid analysis or a colorimetric assay instead.
What is a pancreas bioregulator?
A term describing the organising idea behind the Khavinson programme, which fractionated organ extracts on the premise that each contains short peptides carrying tissue-specific regulatory information. Each compound is named for its source organ.
What is the cytogen versus cytomax distinction?
Cytomaxes are peptide-containing tissue extracts. Cytogens are laboratory-synthesised defined sequences designed to reproduce the extract activity. Pancragen is a cytogen, so it can be characterised completely by routine analysis.
What dosage figures are published?
Rodent work in the microgram per kilogram range by parenteral routes. Russian clinical literature describes courses of ten to twenty days at tens to low hundreds of micrograms, rather than continuous exposure.
Why does the course structure matter?
Because it is a consistent feature of how these compounds are described and it differs from the continuous-exposure designs common elsewhere. Reproducing published work means matching the structure as well as the amount.
How large is the counterion correction?
At roughly 561.6 daltons, a single trifluoroacetate at 114 is about 17 percent of the associated mass. Large, though smaller than Vilon where the same counterion is over 29 percent.
What is the first storage priority?
Light protection. Hold lyophilized material cold, sealed, and in an opaque container or its original packaging, and protect it during weighing and reconstitution as well as in storage.
Compliance Statement
Pancragen peptide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its proposed mechanism has not been independently established, and amounts cited on this page are figures from published studies in the species those studies used. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for Pancragen Peptide 20mg